[go: up one dir, main page]

AR105044A1 - Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente - Google Patents

Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente

Info

Publication number
AR105044A1
AR105044A1 ARP160101825A ARP160101825A AR105044A1 AR 105044 A1 AR105044 A1 AR 105044A1 AR P160101825 A ARP160101825 A AR P160101825A AR P160101825 A ARP160101825 A AR P160101825A AR 105044 A1 AR105044 A1 AR 105044A1
Authority
AR
Argentina
Prior art keywords
solution
neuroactive steroid
container
solutions
methods
Prior art date
Application number
ARP160101825A
Other languages
English (en)
Inventor
Hunke William
Watson Paul
Jean Robichaud Albert
G Salituro Francesco
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57546448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR105044(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of AR105044A1 publication Critical patent/AR105044A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N30/06—Preparation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • A61L2103/05—

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)

Abstract

Una solución acuosa farmacéuticamente aceptable que comprende un esteroide neuroactivo, una sulfobutil éter de b-ciclodextrina y una solución amortiguadora; en donde: la solución es una solución estable con un pH de entre aproximadamente 3 y aproximadamente 9, por ejemplo, a temperatura ambiente, durante por lo menos 1, 2, 3, 4 semanas; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 meses; 1, 2, 3 años o más; la solución amortiguadora está presente a una concentración de por lo menos 0,1 mM; o la solución permanece sustancialmente libre de impurezas (por ejemplo, la solución está sustancialmente libre de impurezas a temperatura ambiente durante por lo menos 1, 2, 3, 4 semanas; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 meses; 1, 2, 3 años o más). Reivindicación 9: La solución de la reivindicación 1, caracterizada porque el esteroide neuroactivo es alopregnanolona. Reivindicación 10: La solución de la reivindicación 1, caracterizada porque el esteroide neuroactivo es un estrol. Reivindicación 31: La solución amortiguadora de la reivindicación 26, caracterizada porque la solución amortiguadora se selecciona del grupo que consiste en citrato, fosfato, acetato, lactato, gluconato, malato, succinato y tartrato y mezclas de los mismos. Reivindicación 43: La solución de la reivindicación 1, caracterizada porque el esteroide neuroactivo se formula con un 2,5, 5, 6, 7,5, 10, 15, 20, 30% p/v o más de sulfobutiléter-b-ciclodextrina.
ARP160101825A 2015-06-18 2016-06-16 Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente AR105044A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562181550P 2015-06-18 2015-06-18

Publications (1)

Publication Number Publication Date
AR105044A1 true AR105044A1 (es) 2017-08-30

Family

ID=57546448

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101825A AR105044A1 (es) 2015-06-18 2016-06-16 Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente

Country Status (21)

Country Link
US (3) US20190008873A1 (es)
EP (1) EP3310394A4 (es)
JP (3) JP2018521987A (es)
KR (1) KR20180018730A (es)
CN (2) CN108025087A (es)
AR (1) AR105044A1 (es)
AU (2) AU2016279000A1 (es)
BR (1) BR112017026909A2 (es)
CA (1) CA2988262A1 (es)
CO (1) CO2018000137A2 (es)
HK (1) HK1246676A1 (es)
IL (3) IL280082B2 (es)
JO (1) JO3759B1 (es)
MA (1) MA45276A (es)
MX (3) MX2017016660A (es)
PE (2) PE20180489A1 (es)
PH (2) PH12021552011A1 (es)
SG (1) SG10202012285QA (es)
TW (2) TW202408459A (es)
WO (1) WO2016205721A1 (es)
ZA (1) ZA201708412B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL294306B2 (en) 2012-08-21 2024-01-01 Sage Therapeutics Inc Methods of treating epilepsy or status epilepticus
BR112015026380A8 (pt) 2013-04-17 2019-12-31 Sage Therapeutics Inc esteróides de c21-n-pirazolil 19-nor c3,3-dissubstituídos e métodos de uso destes
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
EP3719029A1 (en) 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Compositions for inducing sedation
AR109393A1 (es) 2016-08-23 2018-11-28 Sage Therapeutics Inc Un esteroide 19-nor-c21-pirazolilo c3,3-disustituido cristalino
EP3579842A4 (en) 2017-02-10 2020-12-23 Asarina Pharma AB 3-BETA-HYDROXY-5-ALPHA-PRÉGNAN-20-ONE FOR USE IN THE TREATMENT OF ESSENTIAL TREMMENTS
JP2021505608A (ja) 2017-12-08 2021-02-18 セージ セラピューティクス， インコーポレイテッド ＣＮＳ障害を処置するためのジュウテリウム化された２１−［４−シアノ−ピラゾール−１−イル］−１９−ノル−プレガン−３．α−オール−２０−オン誘導体
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
CN114544822B (zh) * 2020-11-24 2023-10-24 重庆医科大学 检测血浆中溶血磷脂酰胆碱(22:0)的试剂在制备抑郁症检测试剂盒中的用途
US20230321116A1 (en) * 2022-02-16 2023-10-12 Lipocine Inc. 3Alpha-OH-5Beta-Pregnan-20-One Compositions and Methods for Treating Central Nervous System Disorders

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3117142A (en) * 1961-03-01 1964-01-07 Roussel Uclaf Novel preparation of estradiol and estrone
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US6316613B1 (en) 1997-07-25 2001-11-13 Beckman Coulter, Inc. Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US7781421B2 (en) 2003-05-29 2010-08-24 Washington University Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steriods
AU2004312096A1 (en) * 2003-12-31 2005-07-21 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US7892483B2 (en) * 2004-03-12 2011-02-22 Cipla Limited Sterilization process
ITMI20041763A1 (it) 2004-09-16 2004-12-16 Altergon Sa Nuove formulazioni iniettabili contenenti progesterone
CN106667918A (zh) * 2005-11-28 2017-05-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法
JP2009526860A (ja) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー 安定したコルチコステロイド混合物
US20090312364A1 (en) * 2006-12-20 2009-12-17 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP2155204B1 (en) 2007-06-15 2016-08-17 Research Triangle Institute Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
AU2009219230A1 (en) * 2008-02-26 2009-09-03 Emory University Steroid analogues for neuroprotection
WO2011088503A1 (en) 2010-01-21 2011-07-28 Goodchild Investments Pty Ltd Anaesthetic formulation
JP5856162B2 (ja) * 2010-07-26 2016-02-09 ウオーターズ・テクノロジーズ・コーポレイシヨン 粒度分布の狭い実質的に非多孔質のハイブリッドコアを含む表面多孔質材料
FR2973031B1 (fr) 2011-03-23 2013-11-29 Univ Strasbourg Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
AU2012323888A1 (en) 2011-10-14 2014-05-29 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
CN103998046B (zh) * 2011-11-29 2021-04-06 优奥斯私人有限公司 包含环糊精和疏水性药物的可注射药物组合物的防腐方法
RU2681835C2 (ru) * 2012-01-23 2019-03-13 Сейдж Терапьютикс, Инк. Лекарственные формы нейроактивных стероидов и способы лечения нарушений цнс
WO2013188792A2 (en) 2012-06-15 2013-12-19 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
IL294306B2 (en) 2012-08-21 2024-01-01 Sage Therapeutics Inc Methods of treating epilepsy or status epilepticus
AU2013352141B2 (en) * 2012-11-30 2018-04-05 The Regents Of The University Of California Anticonvulsant activity of steroids
SI3392260T1 (sl) 2012-12-18 2023-01-31 Washington University Nevroaktivni 19-alkoksi-17-substituirani steroidi, uporabni pri postopkih zdravljenja
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
BR112015026380A8 (pt) 2013-04-17 2019-12-31 Sage Therapeutics Inc esteróides de c21-n-pirazolil 19-nor c3,3-dissubstituídos e métodos de uso destes
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
CN117304245A (zh) 2013-04-17 2023-12-29 萨奇治疗股份有限公司 刺激神经活性的19-去甲类固醇及其使用方法
AU2014290400B2 (en) 2013-07-19 2019-12-05 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3488852B1 (en) 2013-08-23 2020-10-28 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
AU2016214996B2 (en) * 2015-02-06 2021-03-04 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders

Also Published As

Publication number Publication date
US20190350944A1 (en) 2019-11-21
AU2021250982A1 (en) 2021-11-18
TW201717961A (zh) 2017-06-01
CN108025087A (zh) 2018-05-11
JO3759B1 (ar) 2021-01-31
IL315367A (en) 2024-11-01
EP3310394A1 (en) 2018-04-25
TWI805540B (zh) 2023-06-21
HK1246676A1 (zh) 2018-09-14
PH12021552011A1 (en) 2022-05-02
US20230141665A1 (en) 2023-05-11
MX2017016660A (es) 2018-05-17
SG10202012285QA (en) 2021-01-28
KR20180018730A (ko) 2018-02-21
MX2022016155A (es) 2023-02-22
JP7374954B2 (ja) 2023-11-07
RU2018101711A (ru) 2019-07-18
PH12017502355A1 (en) 2018-06-25
AU2016279000A1 (en) 2018-02-01
IL280082B2 (en) 2025-02-01
JP2018521987A (ja) 2018-08-09
JP2023026616A (ja) 2023-02-24
CA2988262A1 (en) 2016-12-22
PE20180489A1 (es) 2018-03-07
CO2018000137A2 (es) 2018-05-31
IL280082A (en) 2021-03-01
MA45276A (fr) 2018-04-25
CN113181112A (zh) 2021-07-30
MX2022012383A (es) 2022-10-31
IL280082B1 (en) 2024-10-01
US20190008873A1 (en) 2019-01-10
BR112017026909A2 (en) 2018-08-14
JP2021127350A (ja) 2021-09-02
ZA201708412B (en) 2022-12-21
EP3310394A4 (en) 2019-04-10
PE20221726A1 (es) 2022-11-04
IL256251A (en) 2018-04-30
RU2018101711A3 (es) 2019-12-12
WO2016205721A1 (en) 2016-12-22
AU2021250982B2 (en) 2024-03-14
TW202408459A (zh) 2024-03-01

Similar Documents

Publication Publication Date Title
AR105044A1 (es) Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente
AR108591A1 (es) Composición acuosa que contiene atropina
ES2656901T3 (es) Una formulación estabilizada de pemetrexed
PE20141152A1 (es) Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
AR082049A1 (es) Formulaciones liquidas de rupatadina fumarato
EA201590730A1 (ru) Способ и стероидная композиция для местного применения
CR20160099A (es) Formulación de inhibidores de la syk
PE20071244A1 (es) Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas)
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
MX369642B (es) Sales de dasatinib.
AR088296A1 (es) Citramida de rasagilina, proceso de preparación y composicion farmaceutica
CR20140053A (es) Formulaciones de ácido desoxicólico y sales del mismo
MX374628B (es) Formulacion que comprende un agente hipolipidemico.
PE20171246A1 (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos
PH12016502418A1 (en) Recuronium preparation with improved stability
AR090457A1 (es) Composicion topica semisolida conteniendo pirfenidona y dialil oxido de disulfuro modificado (odd-m) para eliminar o prevenir el acne
MX2019007239A (es) Nueva formulacion que comprende un derivado de bencimidazol.
BR112015029504A2 (pt) inibidores quinase
MX2018009514A (es) Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1.
AR087371A1 (es) Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos
PH12017500388B1 (en) Tadalafil oral dispersible film and preparing method thereof
MX2019014677A (es) Compuestos de estra-1,3,5(10)-trien-17-ona sustituida con 15.beta.-[3-propanamido] y sus 17-oximas para usarse en la inhibicion de 17.beta.-hidroxiesteroides deshidrogenasas.
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.
PE20151300A1 (es) Composicion antifungica topica para el tratamiento de onicomicosis

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FB Suspension of granting procedure